1. Banaschewski T, Bauer M, Bea M, Döpfner M, Geld M, Grosse KP et al. Langfassung der S3 Leitlinie Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. AWMF-Registernummer 028–045. Stand: 5/2017; www.awmf.org/leitlinien/detail/ll/028-045.html (letzter Zugriff: 22.4.2022).
2. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples;Biederman;Arch Gen Psychiatry,1992
3. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study;Biederman;J Am Acad Child Adolesc Psychiatry,1997
4. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review;de Crescenzo;Evid Based Ment Health,2017
5. Genetic heterogeneity in attention-deficit hyperactivity disorder (ADHD): gender, psychiatric comorbidity, and maternal ADHD;Faraone;J Abnorm Psychol,1995